Form Type:  SC 13G/A
Filing Date:  7/11/2022 
CIK:  0001650664 
Address:  11 HURLEY ST. 
City, State, Zip:  CAMBRIDGE, Massachusetts 02141 
Telephone:  617-401-9000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.34 (-3.28%)  
Trade Time: 
Nov 25  
Market Cap: 
Trade EDIT now with 

© 2022  
Description of Business
We are a leading, clinical stage gene editing company dedicated to developing potentially transformative gene editing medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for diseases with high unmet need.
Register and access this filing in: